



# MARKET RELEASE

21 April 2017

**SIRTEX MEDICAL LIMITED**

**TRADING HALT**

The securities of Sirtex Medical Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Wednesday, 26 April 2017 or when the announcement is released to the market.

Security Code:           SRX

Johanna O’Shea  
**ADVISER, LISTINGS COMPLIANCE (SYDNEY)**



Sirtex Medical Ltd  
ABN 35 078 166 122  
Level 33  
101 Miller Street  
North Sydney, 2060  
Phone +61 2 9964 8420  
www.sirtex.com

21<sup>st</sup> April 2017

Kimberley Brown  
ASX Limited  
Exchange Centre  
20 Bridge Street  
Sydney, NSW, 2000

**BY EMAIL:** [kimberley.brown@asx.com.au](mailto:kimberley.brown@asx.com.au); [tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

Dear Kimberley

### **Trading Halt Request**

In accordance with ASX Listing Rule 17.1, Sirtex Medical Limited (**Company**) requests a trading halt in the shares of the Company, effective immediately.

The trading halt is requested to provide the Company time to review the presentation of the SARAH clinical study results at the European Association for the Study of the Liver – The International Liver Congress™ (EASL/ILC) event in Amsterdam, the Netherlands on Saturday 22<sup>nd</sup> April. The abstract release, presentation and associated clinical discussions are expected to yield important new information on the SARAH study and interpretation of its findings.

The Company expects to be in a position to issue an announcement prior to the commencement of normal trading on Monday, 24<sup>th</sup> April 2017. The trading halt is requested to be in place until such time as the announcement is made to the market.

The Company is not aware of any reason why the trading halt should not be granted, nor is it aware of any other information necessary to inform the market about the trading halt.

Yours sincerely

A handwritten signature in black ink, appearing to read 'Darren Smith', with a long horizontal flourish extending to the right.

**Darren Smith**  
**Chief Financial Officer and Company Secretary**  
**Sirtex Medical Limited**